NOT KNOWN FACTUAL STATEMENTS ABOUT HEMGENIX

Quantity of eligible sufferers: CDEC reviewed the uncertainty in the quantity of clients with reasonably critical to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who will be categorised as owning moderate or reasonable ailment could possibly have a s